In a ceremony December 12 at the CURE Annual Holiday Party at Alexion in New Haven, the 2017 CURE Entrepreneur of the Year award was presented to Jennifer Good of Trevi Therapeutics and Dr. Vlad Coric of Biohaven Pharmaceuticals, two biotechnology executives whose work has positively affected bioscience in Connecticut and beyond.

Jennifer L. Good is the co-founder of Trevi Therapeutics and serves as a director as well as president and CEO of the company. At Trevi, Ms. Good has successfully raised $100 million, hired a high-caliber team of biotech innovators, and overseen the development of Trevi’s drug candidate from preclinical through to Phase 3 for treatment of chronic severe pruritis in various medical conditions. Colleagues have described her as “inspiring, visionary, and a natural leader.”

Vlad Coric, MD, is the CEO and a director of Biohaven Pharmaceuticals. He has assembled and led a team of industry veterans, advancing a broad portfolio of first-in-class and best-in-class drug candidates for patients with severe neurological conditions, and raising approximately $194 million in Biohaven’s IPO in May 2017. Dr. Coric was cited as “warm, personable, and generous with his time”, conveying an “optimism and positive approach [that is] energizing and productive.”

The Entrepreneur of the Year award was established by CURE and the law firm of Shipman & Goodwin to acknowledge the importance of showcasing unique accomplishments of entrepreneurs in the Connecticut community.

Dormer Stephen, a partner at Shipman & Goodwin, said, “Both Jennifer Good and Dr. Coric’s accomplishments and contributions within the Connecticut bioscience community are a great fit for the 2017 CURE Entrepreneur of the Year award, and we are proud to recognize each of them for their hard work and dedication.”